Connect with us

Media OutReach

Bupa Hong Kong Connects More Customers to Flexible and Affordable Outpatient Care with Blua Health Pass

Published

on

Blua Health Pass promotes everyday wellness by making outpatient care more accessible across digital and in-person touchpoints, under Bupa’s commitment to Together for Your Health

HONG KONG SAR – Media OutReach Newswire – 18 August 2025 – To more effectively meet the evolving needs of healthcare customers in Hong Kong, Bupa Hong Kong is now launching Blua Health Pass, a subscription-based outpatient healthcare solution designed to deliver accessible local care. This programme empowers individuals to take control of their health with ease, flexibility and affordability.

With plans starting at just HK$250, Blua Health Pass connects customers to preventative care that meets the everyday wellness needs of today’s workforce and health-conscious individuals.

Developed to provide greater choice, Blua Health Pass offers seamless access to a wide range of outpatient services across digital and physical touchpoints—making it even more convenient to book appointments with general practitioners, specialists, Traditional Chinese Medical practitioners and physiotherapists. Customers can also track health progress, complete health missions and receive wellness recommendations available through the Blua Health app.

Blua Health, Hong Kong’s leading one-stop AI-powered mobile app, offers a range of digitally-enabled services including video consultations and ePharmacy¹, rewards for health missions, insurance management², and claims and other results review.

Three New Plans to Support Everyday Healthcare Needs

Blua Health Pass³ offers three levels of protection, with exclusive rates of up to 67% on standard service fees at around 380 service points and more than 20 specialties across Hong Kong. Customers can take advantage of priority eBooking on the Blua Health App for less wait time, AI-powered health assessments, digital prescription ordering and healthy living rewards. The three plans include:

  • Blua Health Pass Lite, priced at HK$250, is ideal for individuals exploring Bupa’s network healthcare services.
  • Moving up, the Blua Health Pass Plus is available for HK$780 per year, catering to those who seek more frequent healthcare interactions, providing greater access and savings on a variety of services.
  • The most comprehensive offering is the Blua Health Pass Flex, which costs HK$1,800 annually. This premium option is intended for individuals requiring broad and frequent access to outpatient care. Subscribers to the Flex plan can enjoy up to 15 outpatient visits per year, with co-payments ranging from HK$60 to HK$120. The plan covers a wide range of services, including general practice and specialist consultations, physiotherapy, Traditional Chinese Medicine, as well as diagnostic imaging, lab tests, vaccinations, and more.

Yuman Chan, General Manager of Bupa Insurance Business in Hong Kong, said, “Blua Health Pass helps to fill the outpatient medical needs for individuals without comprehensive insurance: whether they are freelancing, working for a startup, retired, or simply seeking an easier and more affordable way to access everyday care. Members can also stay in control of their healthcare management anytime, anywhere, and fully harness technology to integrate health into everyday life whilst making preventative care more affordable.”

Sign up for your preferred Blua Health Pass on Blua Health App today. Click this link to subscribe in just five minutes and begin enjoying accessible local care, priority in outpatient appointment bookings and exclusive rates: https://bluahealth.app.link/home


¹Video consultation and ePharmacy features are provided by our medical service provider.

²Insurance management services are offered through myBupa feature of Blua Health. myBupa is offered, distributed and operated by Bupa (Asia) Limited. Blua Health is not a licensed insurance agent of Bupa (Asia) Limited, nor does it represent Bupa to conduct any insurance activities. The fact that Blua Health provides myBupa feature does not constitute and should not be construed as Blua Health conducting any Regulated Activities as defined by the Insurance Ordinance, Chapter 41 of the Laws of Hong Kong, or any insurance activities.

³Blua Health Pass is a subscription-based membership scheme offered, distributed and operated by Blua (Asia) Services Limited, a company registered in Hong Kong under the Bupa Group. Blua Health Pass is not an insurance product. Terms and conditions apply. Please refer to our product leaflet for more details.

Hashtag: #Bupa #BupaHongKong #保柏 #保柏香港 #BluaHealthPass #BluaHealth通行證 #healthcare #日常保健

The issuer is solely responsible for the content of this announcement.

Bupa – An international health insurance specialist

Established in 1947, Bupa’s purpose is helping people live longer, healthier, happier lives and making a better world. We are an international healthcare company serving over 60 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers. Bupa has businesses around the world, principally in Australia, the UK, Spain, Poland, Chile, Hong Kong SAR, India, Türkiye, Brazil, Mexico and New Zealand. We also have associate businesses in Saudi Arabia.

Bupa has been a health insurance specialist in Hong Kong since 1976, offering one-stop solutions across domestic and international health insurance, and healthcare services. Our comprehensive medical insurance schemes are tailored to meet individual needs, and we provide health solutions for companies of all sizes. We also have a team of registered nurses, health management professionals, and doctors who provide various expert healthcare support.

Our healthcare provision arm, Quality HealthCare Medical Services (QHMS), became part of Bupa in October 2013. QHMS offers Western Medicine, Traditional Chinese Medicine, Diagnostics & Imaging, Dental, Physiotherapy, Mental Health and Wellness services via a network of over 1,650 provider service points in Hong Kong.

For more information, visit .

Advertisement

Media OutReach

Zuellig Pharma Acquires Cialis® (Tadalafil) from Lilly in three additional markets in Asia

Published

on

SINGAPORE – Media OutReach Newswire – 12 March 2026 – Zuellig Pharma, a leading healthcare solutions company in Asia, today announced that it has acquired all rights, title, and interest in and to Cialis® (Tadalafil), a leading men’s health product from Eli Lilly and Company (“Lilly”) in Hong Kong, Macau and South Korea.

Following the acquisition, Zuellig Pharma will now own the trademarks, marketing authorizations and license manufacturing know-how for Cialis®, a treatment for erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), in 11 markets in Asia, with the expansion of its ownership into three additional markets beyond the original eight. Zuellig Pharma will also continue to promote and distribute the brand in these markets.

The expanded ownership of Cialis® will widen accessibility of the drug to a significant population of men in Asia who are affected by ED and BPH. The acquisition also aligns with Zuellig Pharma’s strategic priority of building a strong portfolio of owned prescription healthcare products as an integrated healthcare solutions company.

“Our acquisition of Cialis® in three additional markets builds on the strong foundation we established two years ago and highlights our proven success in scaling trusted brands effectively through our commercial capabilities and deep expertise. As we broaden our footprint, we remain focused on delivering sustainable growth and advancing our purpose of making in-demand healthcare solutions more accessible to communities in Asia,” said John Graham, CEO of Zuellig Pharma.
Hashtag: #ZuelligPharma #EliLillyandCompany #Cialis #MensHealth #Healthcare #Pharmaceuticals


The issuer is solely responsible for the content of this announcement.

About Zuellig Pharma

Zuellig Pharma is a leading healthcare solutions company in Asia, and our purpose is to make healthcare more accessible to the communities we serve. We provide world-class distribution, commercialization, and clinical trial support services, underpinned by a strong culture of innovation to support the growing healthcare needs in this region. The company was founded a hundred years ago and has grown to become a multibillion-dollar business covering 18 markets with over 12,000 employees. Our people serve more than 200,000 medical facilities and work with over 450 clients, including the top 20 pharmaceutical companies in the world.

Continue Reading

Media OutReach

Ingdan Powers Embodied AI with Humanoid-Style Brain-Cerebellum Chipset to Boost Robotics Ecosystem

Published

on

HONG KONG SAR – Media OutReach Newswire – 12 March 2026 – Ingdan, Inc. (“Ingdan” or the “Company”, stock code: 400.HK; with its subsidiaries (the ”Group”)), a core supplier in the AI computing power supply chain and a leading application technology solutions provider, announces continued progress in strengthening its humanoid robotics ecosystem through an integrated embodied intelligence IC product matrix, supporting the industry’s transition toward large‑scale commercialization.

2026 is widely regarded as a milestone year for humanoid robotics, in which humanoid robots transition from laboratory prototypes and demonstration performances to large‑scale mass production. At CES in January, NVIDIA announced the commercial launch of its physical‑AI core platform Jetson Thor. Tesla is scheduled to officially release the mass‑production engineering version of its Optimus (V3) humanoid robot by the end of March, with plans to initiate million‑unit‑level production lines by the end of 2026—an inflection point widely regarded as the “Model 3 moment” of the humanoid robotics industry. At the same time, Chinese robotics companies such as AGIBOT, Unitree, and Fourier Intelligence have already deployed products at scale in warehousing and logistics scenarios.

Against this backdrop, the upstream hardware focus of the humanoid robotics industry is increasingly converging on “Brain-Cerebellum” collaboration and low‑latency, multi‑joint real‑time control, which are essential to achieving coordinated, smooth, and human‑like robotic motion. During the CMG Spring Festival Gala, robots from multiple companies demonstrated complex coordinated movements and dexterous hand operations, further highlighting the value of this technical direction.

D‑Robotics, originating from the AIoT and robotics division of Horizon Robotics, focuses on edge‑side embodied intelligence solutions characterized by high computing power, integrated computation and control, and low latency. Leveraging its parent company’s long‑term experience in intelligent driving, D‑Robotics has established a precise position in humanoid robot “Brain-Cerebellum” coordination and real‑time joint control.

In November 2025, D‑Robotics unveiled its flagship robotics computing platform S600, with an official release planned for the end of the first quarter of 2026. The S600 platform features a highly integrated humanoid‑style “Brain-Cerebellum” chipset architecture. Its “Brain” configuration combines an 18‑core A78AE CPU with a proprietary Nash‑architecture BPU, delivering 560 TOPS (INT8) edge computing power and supporting efficient deployment of VLA, VLM, LLM, and locomotion models. Its “Cerebellum” configuration integrates a 6‑core R52+ MCU, providing high‑reliability, real‑time motion control.

By integrating CPU, BPU, and real‑time MCU capabilities into a single SoC, S600 enables a closed‑loop architecture encompassing perception, decision‑making, and real‑time action control. This design addresses a key industry challenge in which many edge AI processors lack embedded real‑time MCUs and rely on external controllers, resulting in excessive latency. The integrated MCU supports high‑frequency, high‑precision PWM signal generation based on FOC algorithms, enabling precise motor control and contributing to stable rhythm and natural gait.

The S600 platform has been adopted by multiple robotics companies such as Fourier Intelligence, Booster Robotics, X Square Robot, and ROBOTERA, supporting applications that require stable multi‑joint coordination and smooth motion performance.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

D‑Robotics is a core product line Ingdan distributes . Building on D‑Robotics’ products and combined with its own technical services—such as multi‑sensor fusion development, real‑time closed‑loop tuning, Quantization‑Aware Training (QAT) support, simulation testing, and modular SOM customization—the Group has supported sophisticated customers including Galbot and ROBOTERA, continuously enriching the robotics industry ecosystem.

Looking ahead, Ingdan will continue to focus on the humanoid robotics sector. Leveraging an IC product matrix centered on NVIDIA Jetson and D‑Robotics platforms, the Company aims to further strengthen its AI intelligent terminal capabilities and continue supporting the iterative development of embodied intelligence products.

For investor and media enquiries
Please email to **@****an.com

Hashtag: #Ingdan #Chips #humanoid #D‑Robotics #NVIDIA #Tech

The issuer is solely responsible for the content of this announcement.

Ingdan, Inc.

Ingdan, Inc. (00400.HK) is a core supplier in the AI computing power supply chain and an application technology solutions provider covering both AI infrastructure and AI intelligent terminals. The Company represents a broad portfolio of international semiconductor manufacturers, including NVIDIA, Xilinx, Intel, AMD, and SanDisk, as well as numerous domestic chip vendors. It serves hundreds of robotics manufacturers and Tier‑1 customers and has formed a comprehensive embodied intelligence ecosystem.

Continue Reading

Media OutReach

Snow, Ice, and Performance: 2026 Changan Global Testing Season Arrives in Europe with Back-to-Back Winter Events

Published

on

  • European dealers and journalists experienced the CHANGAN DEEPAL S05 AWD at 2026 Changan Global Testing Season this February.
  • With intelligent AWD and advanced ADAS, the CHANGAN DEEPAL S05 AWD offered uncompromising safety and control on winter roads.

Saalfelden, Austria – Media OutReach Newswire – 12 March 2026 – Following extreme cold tests in Yakeshi, China, the 2026 Changan Global Testing Season made its European debut this February with the Changan Winter Experience in Courmayeur and the Winter Test Drives in Saalfelden. The all-electric CHANGAN DEEPAL S05 AWD was tested on snow and ice—familiar conditions for European drivers—offering dealers and journalists an immersive introduction to Changan’s electric mobility vision through dynamic drives.

Three-time Olympic gold medalist and Milano Cortina 2026 Ambassador Deborah Compagnoni joined the event in Courmayeur, testing the CHANGAN DEEPAL S05 AWD. Her career—defined by determination, control, and reliability—reflects Changan’s core values. “I felt that the principles of trajectory and speed in skiing apply to driving. With this model, you gain confidence on challenging terrain,” she said.

Snow-Validated Performance: The CHANGAN DEEPAL S05 AWD

Tested in Europe, the CHANGAN DEEPAL S05 AWD demonstrated controllable dynamics, reliable traction, and enhanced safety—highlighting its cutting-edge AWD and ADAS. The system adapts seamlessly: ECO/COMFORT modes prioritize RWD efficiency, while AWD will engage automatically when sensors detect slip, high torque demand, or extreme cold below -25°C. SPORT mode delivers permanent 50:50 torque for sharper response. SNOW mode maintains balanced torque with optimized slip control for confident driving on low-grip surfaces.

The intelligent AWD system delivers up to 320 kW power, 502 Nm torque, and 0–100 km/h acceleration in 5.5 seconds. It also improves hill climbing with a 40% gradient capability, ensures stability by actively balancing power to prevent skidding, and enables safer cornering at higher speeds through optimized grip and vehicle dynamics.

Changan Standard: Proven in the Alps, Bound for the World

Changan Standard is defined by a principle: forged in extremes, built for every day. From Yakeshi to the Alps, the test environments are selected to verify specific performance attributes—safety technologies, chassis response, all-wheel-drive calibration, and ADAS in low-grip scenarios. The objective of 2026 Global Testing Season is not to demonstrate extremes, but to confirm consistency: that the same level of safety, control, and stability demonstrated will be replicated in Mexico, Thailand, and Saudi Arabia.

Hashtag: #Changan

The issuer is solely responsible for the content of this announcement.

Continue Reading

Trending